Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PharmacoEconomics - Open Année : 2023

Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial

Dates et versions

hal-04439876 , version 1 (09-11-2023)
hal-04439876 , version 2 (13-02-2024)

Identifiants

Citer

Laurent Fauchier, Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer, et al.. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial. PharmacoEconomics - Open, 2023, ⟨10.1007/s41669-023-00432-z⟩. ⟨hal-04439876v1⟩
66 Consultations
15 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More